ATE544749T1 - Verfahren zur synthetisierung pharmazeutischer salze aus einem faktor-xa-hemmer - Google Patents

Verfahren zur synthetisierung pharmazeutischer salze aus einem faktor-xa-hemmer

Info

Publication number
ATE544749T1
ATE544749T1 AT07863800T AT07863800T ATE544749T1 AT E544749 T1 ATE544749 T1 AT E544749T1 AT 07863800 T AT07863800 T AT 07863800T AT 07863800 T AT07863800 T AT 07863800T AT E544749 T1 ATE544749 T1 AT E544749T1
Authority
AT
Austria
Prior art keywords
inhibitor
factor
pharmaceutical salts
synthesizing pharmaceutical
synthesizing
Prior art date
Application number
AT07863800T
Other languages
English (en)
Inventor
James P Kanter
Keiko Sujino
Sharique Sami Zuberi
Robert Scarborough
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Application granted granted Critical
Publication of ATE544749T1 publication Critical patent/ATE544749T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/90—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having more than three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyridine Compounds (AREA)
AT07863800T 2006-11-02 2007-11-01 Verfahren zur synthetisierung pharmazeutischer salze aus einem faktor-xa-hemmer ATE544749T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86414506P 2006-11-02 2006-11-02
PCT/US2007/083394 WO2008057972A1 (en) 2006-11-02 2007-11-01 Methods of synthesizing pharmaceutical salts of a factor xa inhibitor

Publications (1)

Publication Number Publication Date
ATE544749T1 true ATE544749T1 (de) 2012-02-15

Family

ID=39167635

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07863800T ATE544749T1 (de) 2006-11-02 2007-11-01 Verfahren zur synthetisierung pharmazeutischer salze aus einem faktor-xa-hemmer

Country Status (9)

Country Link
US (2) US8524907B2 (de)
EP (2) EP2404906B1 (de)
CN (1) CN101595092B (de)
AT (1) ATE544749T1 (de)
AU (1) AU2007317376B2 (de)
CA (1) CA2667488C (de)
ES (2) ES2382055T3 (de)
PT (2) PT2077995E (de)
WO (1) WO2008057972A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7696352B2 (en) * 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
RU2440986C2 (ru) 2005-11-08 2012-01-27 Милленниум Фамэсьютикэлс, Инк. СОЛЬ ИНГИБИТОРА ФАКТОРА Ха, СПОСОБ ЕЕ ПОЛУЧЕНИЯ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕЕ ОСНОВЕ, СОСТОЯЩИЕ ИЗ НАЗВАННОЙ КОМПОЗИЦИИ ТАБЛЕТКА, КАПСУЛА И ЛЕПЕШКА, СПОСОБ ЛЕЧЕНИЯ ТРОМБОЗА И СПОСОБ ИНГИБИРОВАНИЯ КОАГУЛЯЦИИ ОБРАЗЦОВ КРОВИ
EA015942B1 (ru) 2006-05-05 2011-12-30 Милленниум Фамэсьютикэлс, Инк. Замещенные имидазолы, композиция на их основе, способ профилактики или лечения нежелательного тромбообразования с их помощью и способ ингибирования коагуляции образцов крови
PT2077995E (pt) * 2006-11-02 2012-05-10 Millennium Pharm Inc Métodos de sintetizar sais farmacêuticos de um inibidor de fator xa
CN101743001B (zh) * 2007-04-13 2013-02-06 千年药品公司 用起因子xa抑制剂作用的化合物的组合抗凝治疗
US8394964B2 (en) 2009-12-17 2013-03-12 Millennium Pharmaceuticals, Inc. Methods of synthesizing factor Xa inhibitors
WO2011084652A2 (en) * 2009-12-17 2011-07-14 Millennium Pharmaceuticals, Inc. Salts and crystalline forms of a factor xa inhibitor
WO2011075602A1 (en) * 2009-12-17 2011-06-23 Millennium Pharmaceuticals, Inc. Methods of preparing factor xa inhibitors and salts thereof
TW201221128A (en) 2010-09-01 2012-06-01 Portola Pharm Inc Crystalline forms of a factor Xa inhibitor
US9200268B2 (en) 2012-12-27 2015-12-01 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
US20140346397A1 (en) 2012-12-27 2014-11-27 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
CN104341343B (zh) * 2013-07-24 2018-09-28 四川海思科制药有限公司 贝曲西班的晶型及其制备方法和用途
CN104693114B (zh) * 2013-12-10 2019-08-16 四川海思科制药有限公司 一种贝曲西班的改进的制备方法
CN105085387A (zh) * 2014-05-20 2015-11-25 四川海思科制药有限公司 贝曲西班盐及其制备方法和用途
EP3078378B1 (de) 2015-04-08 2020-06-24 Vaiomer Verwendung von faktor-xa-inhibitoren zur regulierung von glykämie
WO2017091757A1 (en) 2015-11-24 2017-06-01 Portola Pharmaceuticals, Inc. Isotopically enriched betrixaban
CN105348187B (zh) * 2015-12-02 2017-12-08 安徽省逸欣铭医药科技有限公司 一种贝曲西班结构类似物及其制备方法和用途
CN105732490A (zh) * 2016-03-25 2016-07-06 重庆医科大学 一种贝曲西班的制备方法
EP3293174A1 (de) * 2016-09-09 2018-03-14 Sandoz Ag Kristalline formen von betrixaban
WO2018229796A2 (en) * 2017-06-14 2018-12-20 Mylan Laboratories Limited A process for betrixaban hydrochloride and betrixaban maleate salt
CN108570003A (zh) * 2018-06-01 2018-09-25 浙江宏元药业股份有限公司 一种贝曲西班马来酸盐的一水无定形及其制备方法

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2095619A (en) 1937-10-12 Aryl oxides
CH520657A (de) 1961-09-11 1972-03-31 Wander Ag Dr A Verfahren zur Herstellung mehrbasischer Verbindungen
GB1047245A (de) 1963-02-15
DE3207033C2 (de) 1981-02-27 1984-09-13 Torii & Co., Ltd., Tokyo Amidinverbindungen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Mittel
US4500714A (en) 1981-10-15 1985-02-19 Chugai Seiyaku Kabushiki Kaisha 3-Substituted-ureido-N-pyridyl benzamides
US4588587A (en) 1983-03-01 1986-05-13 Pennsylvania Hospital Method of treatment to inhibit metastasis
JPS59181257A (ja) 1983-03-31 1984-10-15 Chugai Pharmaceut Co Ltd ウレイドベンズアミド誘導体
JP2668231B2 (ja) 1987-12-29 1997-10-27 大日精化工業株式会社 電子写真感光体
AU606808B2 (en) 1988-06-29 1991-02-14 Otsuka Pharmaceutical Factory, Inc. Arylcarboxamide substituted by alkylphosphonates, process for preparing the same and a pharmaceutical composition containing the same
GB9816837D0 (en) 1998-08-04 1998-09-30 Zeneca Ltd Amide derivatives
ZA928276B (en) 1991-10-31 1993-05-06 Daiichi Seiyaku Co Aromatic amidine derivates and salts thereof.
US5612360A (en) 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
CA2151044A1 (en) 1992-12-15 1994-06-23 Terence K. Brunck Novel inhibitors for factor xa
GB9226238D0 (en) 1992-12-16 1993-02-10 Scherer Ltd R P Encapsulation apparatus and process
US5610335A (en) 1993-05-26 1997-03-11 Cornell Research Foundation Microelectromechanical lateral accelerometer
NZ296210A (en) 1994-12-02 1998-05-27 Yamanouchi Pharma Co Ltd Amidinonaphthyl derivatives to inhibit activated blood coagulation factor x
EP0742208A1 (de) 1995-05-05 1996-11-13 Grelan Pharmaceutical Co., Ltd. 2-Ureido-benzamid-Derivate
US5849759A (en) 1995-12-08 1998-12-15 Berlex Laboratories, Inc. Naphthyl-substituted benzimidazole derivatives as anti-coagulants
US5994375A (en) 1996-02-12 1999-11-30 Berlex Laboratories, Inc. Benzamidine derivatives substituted by amino acid and hydroxy acid derivatives and their use as anti-coagulants
JP2000516234A (ja) 1996-08-16 2000-12-05 デュポン ファーマシューティカルズ カンパニー アミジノフェニル―ピロリジン類、アミジノフェニル―ピロリン類、およびアミジノフェニル―イソオキサゾリジン類およびそれらの誘導体
EP0934068A1 (de) 1996-09-09 1999-08-11 Smithkline Beecham Corporation Verbindungen und verfahren
CN1246847A (zh) 1996-12-23 2000-03-08 杜邦药品公司 作为Xa因子抑制剂的含氮杂芳族化合物
ES2196396T3 (es) 1996-12-23 2003-12-16 Bristol Myers Squibb Pharma Co Compuestos heteroaromaticos de 5 miembros conteniendo oxigeno o azufre como inhibidores del factor xa.
EP0993448A1 (de) 1997-06-19 2000-04-19 The Du Pont Merck Pharmaceutical Company (amidino)6-gliedrige aromaten als factor xa inhibitoren
EP1007037A4 (de) 1997-06-26 2004-10-06 Lilly Co Eli Antithrombose mittel
US6313151B1 (en) 1997-06-26 2001-11-06 Eli Lilly And Company Antithrombotic agents
AU8270898A (en) 1997-06-26 1999-01-19 Eli Lilly And Company Antithrombotic agents
IL133623A0 (en) 1997-06-26 2001-04-30 Lilly Co Eli Antithrombotic agents
US5908841A (en) 1997-08-11 1999-06-01 Boehringer Ingelheim Pharmaceuticals, Inc. 5,11-dihydro-6H-dipyrido 3,2-b:2',3'-e!azepine-6-ones and their use in the prevention of treatment of HIV infection
EP1020434A4 (de) 1997-08-27 2000-11-15 Kissei Pharmaceutical 3-amidinoanilin-derivate, inhibitoren des aktivierten blutgerinnungsfaktors x und zwischenpodukte zur herstellung beider
US6140351A (en) 1997-12-19 2000-10-31 Berlex Laboratories, Inc. Ortho-anthranilamide derivatives as anti-coagulants
NZ503809A (en) 1997-12-19 2002-04-26 Schering Ag Ortho-anthranilamide derivatives as anti-coagulants
EP0937711A1 (de) 1998-02-18 1999-08-25 Roche Diagnostics GmbH Neue Thiobenzamide, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel
JPH11302177A (ja) 1998-04-27 1999-11-02 Otsuka Pharmaceut Factory Inc 腎炎治療剤
CN1348446A (zh) 1998-12-09 2002-05-08 美国家庭用品有限公司 含苯二胺基团的含杂环羧酰胺的疱疹病毒硫脲抑制剂
EP1137633A2 (de) 1998-12-09 2001-10-04 American Home Products Corporation Acetamid und substituiertes acetamid enthaltende thioharnstoffe als herpesviren-hemmer
WO2000034268A1 (en) 1998-12-09 2000-06-15 American Home Products Corporation Thiourea inhibitors of herpes viruses
CZ20011957A3 (cs) 1998-12-09 2001-10-17 American Home Products Corporation Thiomočoviny jako inhibitory herpes virů
AU2353900A (en) 1998-12-09 2000-06-26 Wyeth Heterocyclic carboxamide-containing thiourea inhibitors of herpes viruses containing a substituted phenylenediamine group
WO2000034269A1 (en) 1998-12-09 2000-06-15 American Home Products Corporation Thiourea inhibitors of herpes viruses
AU1934600A (en) 1998-12-09 2000-06-26 Wyeth Alpha-methylbenzyl-containing thiourea inhibitors of herpes viruses containing a phenylenediamine group
ATE272633T1 (de) 1998-12-23 2004-08-15 Lilly Co Eli Aromatische amiden
US6632815B2 (en) 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US6720317B1 (en) 1999-09-17 2004-04-13 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
DE60040676D1 (de) 1999-09-17 2008-12-11 Millennium Pharm Inc BENZAMIDE UND ÄHNLICHE INHIBITOREN VON FAKTOR Xa
US6844367B1 (en) 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
ES2254385T3 (es) 2000-02-29 2006-06-16 Millennium Pharmaceuticals, Inc. Benzamidas e inhibidores relacionados del factor xa.
AU776053B2 (en) 2000-03-31 2004-08-26 Astellas Pharma Inc. Diazepan derivatives or salts thereof
RS53403A (sr) * 2000-12-29 2006-10-27 Pfizer Limited Postupak za dobijanje amlodipin maleata
US7312235B2 (en) 2001-03-30 2007-12-25 Millennium Pharmaceuticals, Inc. Benzamide inhibitors of factor Xa
US6627646B2 (en) 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
CN1886398A (zh) 2003-10-09 2006-12-27 米伦纽姆医药公司 作为Xa因子抑制剂的经硫醚取代的苯甲酰胺
JP5020073B2 (ja) 2004-06-18 2012-09-05 ミレニアム ファーマシューティカルズ インク． 第Ｘａ因子阻害剤
US7696352B2 (en) 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
RU2440986C2 (ru) * 2005-11-08 2012-01-27 Милленниум Фамэсьютикэлс, Инк. СОЛЬ ИНГИБИТОРА ФАКТОРА Ха, СПОСОБ ЕЕ ПОЛУЧЕНИЯ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕЕ ОСНОВЕ, СОСТОЯЩИЕ ИЗ НАЗВАННОЙ КОМПОЗИЦИИ ТАБЛЕТКА, КАПСУЛА И ЛЕПЕШКА, СПОСОБ ЛЕЧЕНИЯ ТРОМБОЗА И СПОСОБ ИНГИБИРОВАНИЯ КОАГУЛЯЦИИ ОБРАЗЦОВ КРОВИ
US20090186810A1 (en) 2006-03-27 2009-07-23 Portola Pharmaceuticals, Inc. Potassium channel modulators and platelet procoagulant activity
EA015942B1 (ru) 2006-05-05 2011-12-30 Милленниум Фамэсьютикэлс, Инк. Замещенные имидазолы, композиция на их основе, способ профилактики или лечения нежелательного тромбообразования с их помощью и способ ингибирования коагуляции образцов крови
PT2077995E (pt) * 2006-11-02 2012-05-10 Millennium Pharm Inc Métodos de sintetizar sais farmacêuticos de um inibidor de fator xa
NZ578180A (en) 2006-12-08 2012-02-24 Millennium Pharm Inc Unit dose formulations and methods of treating thrombosis with an oral factor xa inhibitor
EP2114930A2 (de) 2007-01-05 2009-11-11 Millennium Pharmaceuticals, Inc. Faktor-xa-hemmer
CN101743001B (zh) 2007-04-13 2013-02-06 千年药品公司 用起因子xa抑制剂作用的化合物的组合抗凝治疗
NZ599556A (en) 2007-05-02 2013-10-25 Portola Pharm Inc Combination therapy with a compound acting as a platelet adp receptor inhibitor
US8394964B2 (en) * 2009-12-17 2013-03-12 Millennium Pharmaceuticals, Inc. Methods of synthesizing factor Xa inhibitors

Also Published As

Publication number Publication date
EP2077995B1 (de) 2012-02-08
US20100197929A1 (en) 2010-08-05
ES2382055T3 (es) 2012-06-04
CN101595092A (zh) 2009-12-02
US8524907B2 (en) 2013-09-03
PT2404906E (pt) 2015-11-02
AU2007317376A1 (en) 2008-05-15
EP2077995A1 (de) 2009-07-15
EP2404906B1 (de) 2015-07-15
ES2550057T3 (es) 2015-11-04
CA2667488A1 (en) 2008-05-15
HK1133258A1 (en) 2010-03-19
CA2667488C (en) 2015-07-07
CN101595092B (zh) 2012-02-01
US9221758B2 (en) 2015-12-29
EP2404906A1 (de) 2012-01-11
PT2077995E (pt) 2012-05-10
US20140046071A1 (en) 2014-02-13
HK1165426A1 (en) 2012-10-05
AU2007317376B2 (en) 2013-01-17
WO2008057972A1 (en) 2008-05-15

Similar Documents

Publication Publication Date Title
PT2404906E (pt) Métodos de sintetizar sais farmacêuticos de um inibidor de fator xa
EA200970569A1 (ru) Применимые в качестве гербицидных соединений пиридопиразиновые производные
ATE540931T1 (de) Verfahren zur synthese organischer verbindungen
DK2091948T3 (da) Nye inhibitorer af glutaminylcyclase
EA201100666A1 (ru) Тиоамидные соединения, способ их получения и способ их применения
ATE553083T1 (de) Verfahren zur herstellung eines 2- pyridylethylcarbonsäureamidderivats
CY1113716T1 (el) Νεα μεθοδος συνθεσης της αγομελατινης
CY1112829T1 (el) Νεα μεθοδος συνθεσης για την αγομελατινη
ATE539054T1 (de) Verfahren zur herstellung von dihydropyrrolderivaten als zwischenprodukte
CY1112520T1 (el) Βενζυλαμινες, μια διαδικασια για την παραγωγη τους και η χρηση τους ως αντι-φλεγμονωδεις παραγοντες
EA201300250A1 (ru) Оксадиазольные ингибиторы продуцирования лейкотриена
ATE490956T1 (de) Verfahren zur herstellung eines 2- ethylaminopyridinderivats
GEP20115166B (en) 2-ARYLINDOLE DERIVATIVES AS mPGES-I INHIBITORS
ATE497769T1 (de) Verfahren zur herstellung von ibandronat
EA201100696A1 (ru) 1-(арилсульфонил)-4-(пиперазин-1-ил)-1h-бензимидазолы в качестве лигандов 5-гидрокситриптамина-6
EA200701470A1 (ru) Способы получения производных 4-(фенокси-5-метилпиримидин-4-илокси)пиперидин-1-карбоновой кислоты и родственных соединений
ATE465152T1 (de) Verfahren zum herstellen von alkylaniliden aus halogenbenzolderivaten
EA200800502A1 (ru) Соединения 3-аминокарбазола, фармацевтическая композиция, содержащая указанные соединения, и способ их получения
ZA200800091B (en) Method for producing salts of hydrocyanic acid
CY1111573T1 (el) Νεα μεθοδος συνθεσης της αγομελατινης
ATE532516T1 (de) Verfahren zur synthese von glyt-1-hemmern
ATE398118T1 (de) Verfahren zur synthese einer benzimidazolverbindung
EA201001252A1 (ru) Способ получения производных 3,6-дигидро-1,3,5-триазина
EP2061492A4 (de) Verfahren zur linderung von schmerzen durch modifikation von nmda-rezeptoren durch hemmung von src
DE602005020135D1 (de) Verfahren zur veränderung der alkaloidzusammensetzung von mohnpflanzen